EMA blesses ovarian cancer use for Roche's Avastin

Roche's Avastin won a new indication in ovarian cancer in Europe. The European Medicines Agency approved the drug for use in patients with newly diagnosed, advanced ovarian cancer, in combination with chemotherapy. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.